Psychedelics research: Scientists zero in on the ideal dose of LSD to use in psychiatric treatment
Marijuana Stocks, Finance, & InvestingUncategorized March 12, 2021 MJ Shareholders
New research published in Neuropsychopharmacology provides insight into the acute dose dependent effects of LSD. The findings will help in the planning of clinical trials examining the use of the psychedelic drug in patients with psychiatric conditions.
Previous research has provided initial evidence that LSD might be a viable treatment for certain mental disorders when combined with psychotherapy. But these studies have compared a placebo against a single dose of LSD. The authors of the new research set out to scientifically test the effects of LSD across a range of different doses.
“We wanted to generate clinical data on LSD for its later use as medication in patients,” said research Matthias E. Liechti of University Hospital Basel. “The new study provides information on the acute effects of different doses of LSD. This will help to select the right dose for future trials in patient to treat anxiety and depression.”
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
